Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy.
about
Preference for pharmaceutical formulation and treatment process attributesImproving quality of care in inflammatory bowel disease: what changes can be made today?Nonsteroidal anti-inflammatory drugs, gastroprotection, and benefit-riskAssessing patient preferences for treatment options and process of care in inflammatory bowel disease: a critical review of quantitative dataLost in translation: helping patients understand the risks of inflammatory bowel disease therapy.Patients' benefit-risk preferences for chronic idiopathic thrombocytopenic purpura therapies.Assessing the educational needs of Canadian gastroenterologists and gastroenterology nurses: challenges to optimal care in Crohn's Disease.Predicted patient demand for a new delivery system for glaucoma medicine.A new tool to measure the burden of Crohn's disease and its treatment: do patient and physician perceptions match?Risk of lymphoma associated with combination anti-tumor necrosis factor and immunomodulator therapy for the treatment of Crohn's disease: a meta-analysis.Are adult patients more tolerant of treatment risks than parents of juvenile patients?Making therapeutic decisions in inflammatory bowel disease: the role of patients.The GRADE approach for assessing new technologies as applied to apheresis devices in ulcerative colitis.Patient preferences for surgical versus medical therapy for ulcerative colitis.Update on the risk of lymphoma following immunosuppressive therapy for inflammatory bowel disease.Real-time tool to display the predicted disease course and treatment response for children with Crohn's disease.A framework for organizing and selecting quantitative approaches for benefit-harm assessment.Effects of simplifying choice tasks on estimates of taste heterogeneity in stated-choice surveysA descriptive review on methods to prioritize outcomes in a health care context.Value of Genetic Testing for Hereditary Colorectal Cancer in a Probability-Based US Online SampleA formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice.Patient perspectives on the impact of Crohn's disease: results from group interviews.Words that make pills easier to swallow: a communication typology to address practical and perceptual barriers to medication intake behaviorPatient Preferences for Injectable Treatments for Multiple Sclerosis in the United States: A Discrete-Choice Experiment.Taking Crohn's disease personallyPatients' willingness to accept the risks and benefits of new treatments for chronic hepatitis C virus infection.Tumor necrosis factor α inhibitor therapy and cancer risk in chronic immune-mediated diseasesMethodologic evaluation of adaptive conjoint analysis to assess patient preferences: an application in oncology.How much risk are emergency department patients willing to accept to avoid diagnostic testing.Anti-adhesion molecule therapy for inflammatory bowel diseaseQuantifying benefit-risk preferences for medical interventions: an overview of a growing empirical literature.Stopping, continuing, or restarting immunomodulators and biologics when an infection or malignancy develops.Chronic pain patients' treatment preferences: a discrete-choice experiment.Systematic review and meta-analysis: opportunistic infections and malignancies during treatment with anti-integrin antibodies in inflammatory bowel disease.A Note on the Validity and Reliability of Multi-Criteria Decision Analysis for the Benefit-Risk Assessment of Medicines.Understanding Health Literacy and its Impact on Delivering Care to Patients with Inflammatory Bowel Disease.Using Discrete Choice Experiments to Inform the Benefit-Risk Assessment of Medicines: Are We Ready Yet?Patients with Ulcerative Colitis Are More Concerned About Complications of Their Disease than Side Effects of Medications.Treatment preferences of originator versus biosimilar drugs in Crohn's disease; discrete choice experiment among gastroenterologists.Psoriasis patients' willingness to accept side-effect risks for improved treatment efficacy.
P2860
Q26741298-B33CA39E-8B92-4A3C-A07B-1FAEBF825A1FQ26859105-BB4AAB54-B3D8-48FD-B06A-008542E53163Q26864640-9B33BB28-5046-401E-82DE-5518E87895FAQ26864906-33558BD9-37C7-4F90-997D-FCE61B9DB372Q30498145-775DEA91-B2D4-46A7-BE68-A0B19A7B28D5Q33388078-6D931F88-9682-49EE-8B62-1D8A510A86D1Q33586869-DAAA90DA-966D-453C-B4E3-0F938CE0C372Q33597413-93CBB885-BF58-4A2D-A1B0-01B1BBC27FE4Q33756885-3C22F8AE-B3D8-42F8-B72D-243843BC5344Q33756929-AC11E4F9-EC06-429B-AFB3-694E095CAD82Q33761151-B2F8071F-4B72-4D32-8929-ED7F181C4879Q33941262-27951F41-F565-403E-B247-18F36D795F07Q34011689-E9968DE1-43C7-4F4F-8EDD-4D51EA47EBCCQ34065549-5811219A-92A7-421F-99A8-801A457158A5Q34078707-2BFC6E1D-06F7-46B3-B617-83DBF04E432EQ34388523-962CE4B6-F0A2-4619-9084-3AF059502439Q34481196-C25C3DC1-EBFA-42AB-93A5-ADC36C54C724Q35153269-C7B2F5C2-E5E4-41A6-944B-D150E5C9384FQ35231568-B3ADD2D9-DAE5-4AD0-B83F-C095C36BBBEAQ35850612-78F3EDB9-84B5-4F21-841C-D27D347B8927Q35854145-F18B9D11-CE42-43DC-AE2C-D3F452E0965FQ36144557-7E8D2FDA-829D-4A5B-82EA-A61C9A55DB23Q36479513-F2885AB4-C70D-4D55-B5E6-6EAC4D0824D2Q36698871-C837EC19-8ADD-4B2F-8DE8-6DA256A64B0BQ36919248-7A3E0BFB-1E8C-4688-83BD-DB0D980B79BEQ37021514-9555D329-499F-4643-A1B2-F27C1791B04DQ37186231-635AC050-3AF9-4145-825D-BD9991101098Q37332615-2E61BBC1-74E7-43B3-BD73-AEC76AF46994Q37709813-6AEFD7FA-E15A-4A28-A693-925C6223773FQ37823325-22188A0D-58C3-4A9D-8C9B-05FC337E4383Q38103514-739BC231-0E03-4506-9814-0733E302AEBAQ38197891-6AADCDBC-49B1-458C-BDC3-2CD527F72151Q38221971-0AC69BD7-5F8F-469B-BDC4-BACF6DEDB2DAQ38436580-310D3B65-6EDB-4021-8052-F926FAFE4ADBQ38583668-60EB7C0A-26E4-42BA-9DCE-D3FC16A3CCF2Q38643586-3D793DAC-9245-4657-A0C9-9A03B3803B63Q38768040-BA4AC3D9-4538-45B7-BFF4-5DD683968A1BQ38898828-E638859A-A5E1-47E8-88E9-FFC35F679638Q40851924-DED042B3-0950-45F5-89D7-A49A6C36C3FAQ41255645-9EEDC94D-8ACB-4400-AFED-6EBC04AD46B4
P2860
Crohn's disease patients' risk-benefit preferences: serious adverse event risks versus treatment efficacy.
description
2007 nî lūn-bûn
@nan
2007年の論文
@ja
2007年論文
@yue
2007年論文
@zh-hant
2007年論文
@zh-hk
2007年論文
@zh-mo
2007年論文
@zh-tw
2007年论文
@wuu
2007年论文
@zh
2007年论文
@zh-cn
name
Crohn's disease patients' risk ...... sks versus treatment efficacy.
@en
type
label
Crohn's disease patients' risk ...... sks versus treatment efficacy.
@en
prefLabel
Crohn's disease patients' risk ...... sks versus treatment efficacy.
@en
P2093
P1433
P1476
Crohn's disease patients' risk ...... isks versus treatment efficacy
@en
P2093
Bruce E Sands
Carol Mansfield
Corey A Siegel
David W Miller
F Reed Johnson
Semra Ozdemir
P304
P356
10.1053/J.GASTRO.2007.04.075
P407
P50
P577
2007-05-03T00:00:00Z